Austar Lifesciences Limited logo

Austar Lifesciences Limited

6118.HK

HKSEHealthcareMedical - Devices

Latest quote

HK$0.77

+HK$0.035 · +4.76%

Aug 24, 10:25 AM HKTData delayed

6118.HK company overview

Regular session · HKT · Market data may be delayed.

Company profile

Company website

Austar Lifesciences Limited functions as an investment holding company, delivering integrated engineering and technology solutions to pharmaceutical production facilities and research institutions globally, with a significant presence in Mainland China. Its business activities are structured across six primary divisions: liquid and bioprocessing systems; controlled environment and automated monitoring systems; powder and solid material handling systems; Good Manufacturing Practice (GMP) adherence services; life science expendables; and the brokerage and supply of pharmaceutical machinery. The company's product portfolio is extensive, including systems for pharmaceutical water, liquid preparation, and bioprocessing; powder and solid processing units; clean utility infrastructure; and advanced cleanroom technology. They also supply automated control and monitoring systems, freeze-dryers, sterile filling equipment, and visual inspection apparatus. Furthermore, Austar provides products for pharmaceutical contamination control, aseptic packaging and containment, biosafety and lab animal equipment and consumables, single-use bioprocess components, and offers holistic laboratory setup solutions. Beyond its product offerings, Austar Lifesciences extends a wide array of professional services, such as design and engineering, quality risk management, expert consultation, research and development assistance, process optimization, and digitalization strategies. The company also offers post-sale support, on-site services, system upgrades, facility relocation guidance, and comprehensive asset management. Additionally, it serves as an agent and distributor for pharmaceutical equipment, providing associated assembly and pre-assembly services. Established in 1991, Austar Lifesciences Limited is headquartered in Shanghai, China.

Industry
Medical - Devices
Sector
Healthcare
Headquarters
CN
CEO
Kwok Keung
Listed since
Nov 7, 2014
Employees
1,468

Market position

Day range

Current HK$0.77

52-week range

Current HK$0.77

Open
HK$0.75
Previous close
HK$0.735
Volume
26K
0.41× average
Average volume
63.11K
Average daily volume
Market cap
394.69M HKD
Beta
0.84
Market reference 1
50-day average
HK$0.7065
+8.99% above average
200-day average
HK$0.8172
-5.77% below average

Financials

Financial snapshot

Latest / TTM

Valuation & yield

Enterprise value
467.78M CNY
P/E (TTM)
10.05×
P/B (TTM)
0.44×
P/S (TTM)
0.22×
EV / EBITDA
6.4×
Earnings yield
8.44%
Free cash flow yield
24.90%
Dividend yield
0.00%

Profitability & efficiency

Gross margin
19.16%
Operating margin
3.54%
Net margin
2.21%
Return on equity
4.11%
Return on assets
1.59%
Return on invested capital
3.06%

Financial health

Debt / equity
0.42×
Current ratio
1.36×

Earnings

Latest EPS result
0.02

EPS: actual versus estimate

Recent quarterly results

ActualEstimate
Estimates unavailable
Quarterly EPS actual values compared with estimates0.560.30.05-0.21Q2 '21Q4 '21Q3 '22Q1 '23Q3 '23Q1 '24Q3 '24Q1 '25
Q2 2021, reported Jun 30, 2021: actual 0.51, estimate —, surprise —, Comparison unavailable. Q4 2021, reported Dec 31, 2021: actual 0.142, estimate —, surprise —, Comparison unavailable. Q3 2022, reported Aug 29, 2022: actual 0.105, estimate —, surprise —, Comparison unavailable. Q1 2023, reported Mar 29, 2023: actual 0.092, estimate —, surprise —, Comparison unavailable. Q3 2023, reported Aug 30, 2023: actual -0.084, estimate —, surprise —, Comparison unavailable. Q1 2024, reported Mar 27, 2024: actual -0.159, estimate —, surprise —, Comparison unavailable. Q3 2024, reported Aug 28, 2024: actual 0.012, estimate —, surprise —, Comparison unavailable. Q1 2025, reported Mar 26, 2025: actual 0.021, estimate —, surprise —, Comparison unavailable.

Revenue: actual versus estimate

Recent quarterly results

ActualEstimate
Estimates unavailable
Quarterly Revenue actual values compared with estimates1.48B1.22B956.16M695.92MQ2 '21Q4 '21Q3 '22Q1 '23Q3 '23Q1 '24Q3 '24Q1 '25
Q2 2021, reported Jun 30, 2021: actual 1.03B HKD, estimate —, surprise —, Comparison unavailable. Q4 2021, reported Dec 31, 2021: actual 1.42B HKD, estimate —, surprise —, Comparison unavailable. Q3 2022, reported Aug 29, 2022: actual 1.29B HKD, estimate —, surprise —, Comparison unavailable. Q1 2023, reported Mar 29, 2023: actual 1.28B HKD, estimate —, surprise —, Comparison unavailable. Q3 2023, reported Aug 30, 2023: actual 994.32M HKD, estimate —, surprise —, Comparison unavailable. Q1 2024, reported Mar 27, 2024: actual 934.45M HKD, estimate —, surprise —, Comparison unavailable. Q3 2024, reported Aug 28, 2024: actual 752.72M HKD, estimate —, surprise —, Comparison unavailable. Q1 2025, reported Mar 26, 2025: actual 850.49M HKD, estimate —, surprise —, Comparison unavailable.

6118.HK peers

Continue in GoAI

Research 6118.HK

research.disclaimer